KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

NovoCure (NVCR) Shares Outstanding (2016 - 2025)

NovoCure's Shares Outstanding history spans 12 years, with the latest figure at $112.5 million for Q4 2025.

  • For Q4 2025, Shares Outstanding rose 3.66% year-over-year to $112.5 million; the TTM value through Dec 2025 reached $112.5 million, up 3.66%, while the annual FY2025 figure was $112.5 million, 3.66% up from the prior year.
  • Shares Outstanding for Q4 2025 was $112.5 million at NovoCure, roughly flat from $112.0 million in the prior quarter.
  • Across five years, Shares Outstanding topped out at $112.5 million in Q4 2025 and bottomed at $103.2 million in Q1 2021.
  • The 5-year median for Shares Outstanding is $106.7 million (2023), against an average of $107.0 million.
  • The largest annual shift saw Shares Outstanding grew 1.04% in 2022 before it rose 3.66% in 2025.
  • A 5-year view of Shares Outstanding shows it stood at $104.0 million in 2021, then rose by 1.04% to $105.0 million in 2022, then grew by 1.93% to $107.1 million in 2023, then increased by 1.35% to $108.5 million in 2024, then increased by 3.66% to $112.5 million in 2025.
  • Per Business Quant, the three most recent readings for NVCR's Shares Outstanding are $112.5 million (Q4 2025), $112.0 million (Q3 2025), and $111.8 million (Q2 2025).